Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by H. Nordahl Christensen
MA18.05 Characteristics and Long-Term OS of Non-Small Cell Lung Cancer Patients Receiving EGFR Tyrosine Kinase Inhibitor Treatment
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
Comparison of the Characteristics of Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations and EGFR‑tyrosine Kinase Inhibitor Treatment in Patients With Non‑small Cell Lung Cancer From Different Ethnic Groups
Experimental and Therapeutic Medicine
Medicine
Cancer Research
Immunology
Microbiology
Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Clinical Implications of High MET Gene Dosage in Non-Small Cell Lung Cancer Patients Without Previous Tyrosine Kinase Inhibitor Treatment
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
JCES 01.18 Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations
OncoTargets and Therapy
Oncology
Pharmacology
ALK, ROS1 and EGFR Next-Generation Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer
Oncology in Clinical Practice
Oncology
Immune-Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients
Jurnal Respirasi
Association of Exon 19 and 21 EGFR Mutation Patterns With Treatment Outcome After First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Development of Crizotinib, a Rationally Designed Tyrosine Kinase Inhibitor for Non-Small Cell Lung Cancer
International Journal of Cancer
Cancer Research
Oncology